(i) Study shows Philogen's proprietary immunocytokines are effective treatment for brain tumors.
(ii) Early promising findings from Philogen's Phase I/II study investigating the safety and efficacy of L19TNF monotherapy in patients with glioblastoma.
(iii) Philogen's proprietary cancer treatment found to be safe and well-tolerated.

Dartmouth scientists found a therapeutic approach that should prevent the development of resistance to targeted anti-tumor drugs in gliomas

Company Reaches Agreement With Deerfield Management Company, L.P. to Purchase Imaging and Service Businesses and Robotics Intellectual Property